ReviewExpert opinion on therapeutic targets2012
Targeting the HGF/Met signaling pathway in cancer therapy.
Review in Expert opinion on therapeutic targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 219 citations in OpenAlex.
- Incidence and risk of fatigue in cancer patients treated with MET inhibitors: A systematic review and meta-analysis.Medicine · 2019Pooled it
- A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- RaPID Selection of Backbone Macrocyclic Peptides Targeting Akt2.Angewandte Chemie (International ed. in English) · 2026Article
- Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance.Journal of pharmaceutical analysis · 2025Review
- HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells.Current cancer drug targets · 2025Article
- Immune and senescence profiles associated with non-AIDS-defining cancer risk in people with HIV: a case-cohort study.Frontiers in immunology · 2025Article
- Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.Cancers · 2024Review
- Oncocytic papillary renal cell carcinoma (OPRCC): 2 case report and literature review.Frontiers in oncology · 2024Article
- TargetingCancers · 2023Review
- Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article).Clinical and experimental medicine · 2023Review
- Overview of Molecular Detection Technologies forCancers · 2023Review
- Article
- Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- HGF/c-Met: A Key Promoter in Liver Regeneration.Frontiers in pharmacology · 2022Review
- Identification of prognostic genes in oral squamous cell carcinoma microenvironment.Cancer biomarkers : section A of Disease markers · 2022Article
- HGF induces oncoprotein HCCR-1 expression through the Wnt/β-catenin pathway in gastric cancer.American journal of translational research · 2022Article
- Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation.International journal of molecular sciences · 2021Article
- Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
introductionUnder normal conditions, hepatocyte growth factor (HGF)-induced activation of its cell surface receptor, the Met tyrosine kinase (TK), is tightly regulated by paracrine ligand delivery, ligand activation at the target cell surface, and ligand-activated receptor internalization and degradation. Despite these controls, HGF/Met signaling contributes to oncogenesis and tumor progression in several cancers and promotes aggressive cellular invasiveness that is strongly linked to tumor metastasis. AREA COVERED: The prevalence of HGF/Met pathway activation in human malignancies has driven rapid growth in cancer drug development programs. The authors review Met structure and function, the basic properties of HGF/Met pathway antagonists now in preclinical and clinical development, as well as the latest clinical trial results. EXPERT OPINION: Clinical trials with HGF/Met pathway antagonists show that as a class these agents are well tolerated. Although widespread efficacy was not seen in several completed Phase II studies, promising results have been reported in lung, gastric, prostate and papillary renal cancer patients treated with these agents. The main challenges facing the effective use of HGF/Met-targeted antagonists for cancer treatment are optimal patient selection, diagnostic and pharmacodynamic biomarker development, and the identification and testing of optimal therapy combinations. The wealth of basic information, analytical reagents, and model systems available concerning HGF/Met oncogenic signaling will continue to be invaluable in meeting these challenges and moving expeditiously toward more effective disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.